Robert Harrington to Stents
This is a "connection" page, showing publications Robert Harrington has written about Stents.
Connection Strength
1.517
-
Should we routinely supplement coronary patients with folate therapy to prevent in-stent restenosis? Am Heart J. 2005 Jun; 149(6):1035-6.
Score: 0.179
-
Bleeding and Mortality With Dual Antiplatelet Therapy: The Rashomon Effect. J Am Coll Cardiol. 2017 04 25; 69(16):2023-2025.
Score: 0.102
-
Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). JACC Cardiovasc Interv. 2015 Mar; 8(3):424-433.
Score: 0.088
-
Response to letter regarding article, "Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial". Circulation. 2014 May 13; 129(19):e494-5.
Score: 0.083
-
Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). J Am Coll Cardiol. 2014 Feb 25; 63(7):619-629.
Score: 0.080
-
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation. 2013 Sep 03; 128(10):1055-65.
Score: 0.079
-
Platelet inhibition with cangrelor during PCI. N Engl J Med. 2013 07 25; 369(4):393-4.
Score: 0.079
-
Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013 Apr 04; 368(14):1303-13.
Score: 0.077
-
Long-term clinical outcomes following coronary stenting. Arch Intern Med. 2008 Aug 11; 168(15):1647-55.
Score: 0.056
-
Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial. Catheter Cardiovasc Interv. 2007 Jul 01; 70(1):43-50.
Score: 0.052
-
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007 Jan 10; 297(2):159-68.
Score: 0.050
-
Frequency, predictors, and outcomes of drug-eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes. Am J Cardiol. 2005 Sep 15; 96(6):750-5.
Score: 0.046
-
Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction. Am J Cardiol. 2005 Feb 01; 95(3):383-6.
Score: 0.044
-
Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):576S-599S.
Score: 0.042
-
Economic impact of drug-eluting stents on hospital systems: a disease-state model. Am Heart J. 2004 Mar; 147(3):449-56.
Score: 0.041
-
Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. Am Heart J. 2004 Mar; 147(3):457-62.
Score: 0.041
-
Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). Am J Cardiol. 2003 Aug 01; 92(3):330-3.
Score: 0.039
-
Distance from the coronary ostium to the culprit lesion in acute ST-elevation myocardial infarction and its implications regarding the potential prevention of proximal plaque rupture. J Thromb Thrombolysis. 2003 Jun; 15(3):189-96.
Score: 0.039
-
Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. J Am Coll Cardiol. 2003 Feb 05; 41(3):386-93.
Score: 0.038
-
Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION. Circ Cardiovasc Interv. 2022 Mar; 15(3):e011069.
Score: 0.036
-
The bent stent. J Invasive Cardiol. 2002 Jan; 14(1):54-6.
Score: 0.035
-
Characteristics, treatment and outcome of patients with non-ST-elevation acute coronary syndromes and multivessel coronary artery disease: observations from PURSUIT (platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrelin therapy). Cardiology. 2002; 98(4):195-201.
Score: 0.035
-
Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y12 Inhibitor Pretreatment. Circ Cardiovasc Interv. 2019 03; 12(3):e007445.
Score: 0.029
-
Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial. J Am Coll Cardiol. 2016 May 10; 67(18):2135-2144.
Score: 0.024
-
Medical Therapy With Versus Without Revascularization in Stable Patients With Moderate and Severe Ischemia: The Case for Community Equipoise. J Am Coll Cardiol. 2016 Jan 05; 67(1):81-99.
Score: 0.023
-
The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. Eur Heart J. 2016 Apr 07; 37(14):1122-30.
Score: 0.023
-
Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet. 2013 Dec 14; 382(9909):1981-92.
Score: 0.020
-
Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009 Dec 10; 361(24):2330-41.
Score: 0.015
-
Changes in patterns of coronary revascularization strategies for patients with acute coronary syndromes (from the CRUSADE Quality Improvement Initiative). Am J Cardiol. 2007 May 01; 99(9):1222-6.
Score: 0.013
-
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med. 2006 Sep 07; 355(10):1006-17.
Score: 0.012